Rocket Pharmaceuticals Toekomstige groei

Future criteriumcontroles 2/6

Rocket Pharmaceuticals zal naar verwachting groeien in winst en omzet met respectievelijk 55.2% en 62.9% per jaar. De winst per aandeel zal naar verwachting groeien met 51.7% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting -35.4% zijn.

Belangrijke informatie

55.2%

Groei van de winst

51.7%

Groei van de winst per aandeel

Biotechs winstgroei	42.4%
Inkomstengroei	62.9%
Toekomstig rendement op eigen vermogen	-35.4%
Dekking van analisten	Good
Laatst bijgewerkt	19 Nov 2024

Recente toekomstige groei-updates

Recent updates

Winst- en omzetgroeiprognoses

DB:9IP1 - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	185	-203	-152	-95	8
12/31/2025	64	-256	-220	-203	12
12/31/2024	0	-268	-243	-214	10
9/30/2024	N/A	-258	-202	-192	N/A
6/30/2024	N/A	-253	-210	-197	N/A
3/31/2024	N/A	-249	-210	-194	N/A
12/31/2023	N/A	-246	-211	-195	N/A
9/30/2023	N/A	-253	-236	-222	N/A
6/30/2023	N/A	-249	-219	-208	N/A
3/31/2023	N/A	-237	-206	-196	N/A
12/31/2022	N/A	-222	-186	-178	N/A
9/30/2022	N/A	-199	-160	-153	N/A
6/30/2022	N/A	-192	-147	-137	N/A
3/31/2022	N/A	-172	-145	-136	N/A
12/31/2021	N/A	-169	-129	-121	N/A
9/30/2021	N/A	-186	-122	-103	N/A
6/30/2021	N/A	-165	-108	-93	N/A
3/31/2021	N/A	-155	-92	-77	N/A
12/31/2020	N/A	-140	-95	-75	N/A
9/30/2020	N/A	-99	-98	-81	N/A
6/30/2020	N/A	-89	-98	-75	N/A
3/31/2020	N/A	-82	-99	-71	N/A
12/31/2019	N/A	-77	-88	-65	N/A
9/30/2019	N/A	-85	-81	-66	N/A
6/30/2019	N/A	-82	-75	-67	N/A
3/31/2019	N/A	-79	-60	-58	N/A
12/31/2018	N/A	-75	-55	-54	N/A
9/30/2018	N/A	-54	-40	-39	N/A
6/30/2018	N/A	-44	N/A	-31	N/A
3/31/2018	N/A	-32	N/A	-24	N/A
12/31/2017	N/A	-20	N/A	-16	N/A
9/30/2017	N/A	-16	N/A	-12	N/A
6/30/2017	N/A	-11	N/A	-9	N/A
3/31/2017	N/A	-9	N/A	-8	N/A
12/31/2016	N/A	-8	N/A	-6	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat 9IP1 de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat 9IP1 de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat 9IP1 de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van 9IP1 ( 62.9% per jaar) zal naar verwachting sneller groeien dan de markt German ( 5.6% per jaar).

Hoge groei-inkomsten: De omzet van 9IP1 ( 62.9% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Er wordt voorspeld dat 9IP1 binnen 3 jaar verliesgevend zal zijn.

Rocket Pharmaceuticals Toekomstige groei

Future criteriumcontroles 2/6

Belangrijke informatie

Recente toekomstige groei-updates

No longer forecast to breakeven

Forecast to breakeven in 2026

Recent updates

New minor risk - Profitability

Rocket Pharmaceuticals, Inc. Announces Completion of Enrollment in Phase 2 Pivotal Trial of RP-A501 for the Treatment of Danon Disease

Rocket Pharmaceuticals, Inc. Appoints Mikael Dolsten to the Board

Rocket Pharmaceuticals, Inc. Provides Regulatory Update on KRESLADI™ (marnetegragene autotemcel; marne-cel)

Rocket Pharmaceuticals Presents Positive Data from Lv Hematology Portfolio At the 27Th Annual Meeting of the American Society of Gene and Cell Therapy (Asgct)

New minor risk - Profitability

Rocket Pharmaceuticals, Inc., Annual General Meeting, Jun 13, 2024

Insider recently sold €284k worth of stock

Rocket Pharmaceuticals, Inc. Announces European Medicines Agency Acceptance of RP-L102 Marketing Authorization Application for the Treatment of Fanconi Anemia

Rocket Pharmaceuticals, Inc. Announces Executive Appointments

No longer forecast to breakeven

CEO & Director recently sold €561k worth of stock

Rocket Pharmaceuticals, Inc. Announces Update on Fda Review Timeline of Kresladi™ (Marnetegragene Autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (Lad-I)

New minor risk - Profitability

Forecast to breakeven in 2026

Rocket Pharmaceuticals, Inc. Appoints R. Keith Woods as Independent, Non-Executive Director

New major risk - Revenue and earnings growth

New minor risk - Profitability

Rocket Pharmaceuticals, Inc. Announces Fda Acceptance of Biologics License Application with Priority Review for Rp-L201 (Marnetegragene Autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (Lad-I)

Rocket Pharmaceuticals Receives European Medicines Agency (Ema) Priority Medicines (Prime) Designation for RP-A501 Gene Therapy for Danon Disease

CEO & Director recently sold €81k worth of stock

Rocket Pharmaceuticals, Inc. Announces FDA Clearance of IND for Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy (ACM)

Insufficient new directors

Insider recently sold €64k worth of stock

Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-A501 Gene Therapy for Danon Disease

Rocket Pharmaceuticals Expands Cardiac Gene Therapy Portfolio with Addition of RP-A601 for PKP2-ACM

Rocket Pharmaceuticals, Inc. Provides Update on Anticipated Registration Path for RP-A501 in Danon Disease Following End-Of-Phase 1 FDA Meeting

Rocket Pharmaceuticals, Inc. (NasdaqGM:RCKT) completed the acquisition of Renovacor, Inc. (NYSEAM:RCOR) from RTW Investments, LP, Chardan Investments 2, LLC and others,

Rocket Pharmaceuticals, Inc. Announces Presentations Highlighting Lentiviral Gene Therapies at the 29th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)

Rocket Pharmaceuticals Announces Positive Updates from Phase 1 Clinical Trial for RP-A501 in Danon Disease at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2022

Rocket Pharmaceuticals, Inc. (NasdaqGM:RCKT) entered into a definitive agreement to acquire Renovacor, Inc. (NYSEAM:RCOR) from RTW Investments, LP and others for $46.7 million.

Rocket Pharmaceuticals, Inc. (NasdaqGM:RCKT) entered into a definitive agreement to acquire Renovacor, Inc. (NYSEAM:RCOR) from RTW Investments, LP and others for $46.7 million.

Rocket Pharmaceuticals, Inc. Appoints Mayo Pujols as Chief Technical Officer and Executive Vice President

Rocket Pharmaceuticals Presents Positive Top-Line Data from Severe Leukocyte Adhesion Deficiency-I Program At the 25Th Annual Meeting of the American Society of Gene and Cell Therapy (Asgct)

Rocket Pharmaceuticals, Inc. Presents Positive Clinical Data from Danon Disease, Fanconi Anemia and Pyruvate Kinase Deficiency Programs at the 25th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)

Rocket Pharmaceuticals, Inc., Annual General Meeting, Jun 13, 2022

Rocket Pharmaceuticals Appoints Fady Malik to Board of Directors

Rocket Pharmaceuticals Appoints Jessie Yeung as Vice President of Investor Relations and Corporate Finance

CEO & Director recently bought €334k worth of stock

Rocket Pharmaceuticals Presents Positive Clinical Data from Company’s Lentiviral Gene Therapies for Treatment of Fanconi Anemia, LAD-I and PKD at the 63rd American Society of Hematology (ASH) Annual Meeting

Rocket Pharmaceuticals, Inc. Presents Positive Clinical Data from Fanconi Anemia, Leukocyte Adhesion Deficiency-I, and Pyruvate Kinase Deficiency Programs at 24Th Annual Meeting of the American Society of Gene and Cell Therapy

Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy Designation for RP-L201 Gene Therapy for Leukocyte Adhesion Deficiency-I

New 90-day high: €52.50

Rocket Pharmaceuticals, Inc. Announces Executive Appointments

Rocket Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $260.000048 million.

Rocket Pharmaceuticals Presents Positive Clinical Data from its Fanconi Anemia and Leukocyte Adhesion Deficiency-I Programs at the 62nd American Society of Hematology Annual Meeting

New 90-day high: €50.00

Rocket Pharmaceuticals Announces Positive Preliminary Clinical Data from Phase 1 Trial of RP-L301 for the Treatment of Pyruvate Kinase Deficiency at the 62nd American Society of Hematology Annual Meeting

New 90-day high: €28.40

Inotek Pharmaceuticals Corporation Receives Funding from the California Institute for Regenerative Medicine for Phase 1 Clinical Trial of RP-L401 for Infantile Malignant Osteopetrosis

Rocket Pharmaceuticals, Inc. Presents Positive LAD-L Clinical Update and Comprehensive IMO Preclinical Review At the European Society for Immunodeficiencies 2020 Meeting

New 90-day high: €25.00

New 90-day high - €22.40

Rocket Pharmaceuticals, Inc.(NasdaqGM:RCKT) dropped from Russell Microcap Index

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven